‘Our strategy is working’: J&J Q3 net profit soars 21.6%

By Kacey Culliney

- Last updated on GMT

Within J&J's consumer health business, its skin care brands Neutrogena and Aveena have performed strongly worldwide [Getty Images]
Within J&J's consumer health business, its skin care brands Neutrogena and Aveena have performed strongly worldwide [Getty Images]

Related tags J&J Johnson & johnson financial results Personal care Skin health Neutrogena Aveena

Personal care major Johnson & Johnson (J&J) has reported a rise in third quarter (Q3) sales and a surge in net profit, bolstered by strong growth in pharma and med tech but also solid results across its global consumer health business.

This week, Johnson & Johnson (J&J) reported sales of €24.3bn ($23.79bn) for the third quarter (Q3) of 2022, up 1.9% on the previous year. Net profit in Q3 surged 21.6% to €4.5bn ($4.45bn) from €3.74bn ($3.66bn) in 2021, a stark contrast to the company’s 23.3% net profit dip in Q2, reported in July​. Adjusted net earnings, excluding intangible amortization expense and special items, sat higher at €6.9bn ($6.7bn) but was down 2.7% on the previous year.

Sales in J&J’s consumer health division – soon to be carved out into standalone business Kenvue – dipped 0.4% to €3.8bn ($3.79bn). Adjusted operational growth, however, which excluded net impact of acquisitions, divestitures and translational currency, grew 4.8%. Growth across the business unit had largely been driven strategic price increases, over-the-counter health products in the US and strong performances of Neutrogena and Aveeno skin care brands worldwide.

‘Solid results across our business segments’

Joaquin Duato, CEO of J&J, said the results demonstrated the company’s “continued strength and resilience”​ across all three of its business units, adding that the company would maintain its 2022 full-year operational sales guidance of 7%.

Duato said J&J remained confident in international business and its ability to continue advancing its “innovative portfolio and pipeline”.

Speaking to analysts on the company’s earnings call, Joseph Wolk, executive VP and CFO of J&J, added: “We are pleased to report solid results across our business segments in the third quarter. We accelerated operational sales growth across all three segments, and we were able to meet earnings expectations despite significant inflationary impacts to input costs. This performance reflects the strength of our business and versatility of our operations despite persistent global macroeconomic challenges.”

Consumer health split – ‘we are making great strides towards the planned separation’

Thibaut Mongon, executive VP and worldwide chairman of consumer health at J&J, told analysts the company was “very proud”​ of what the business unit had achieved in Q3.

“Our strategy is working. Our pricing actions were realised, supply chain constraints eased, and we are also against easier prior year comparables. Our third quarter results reflect those dynamics and really demonstrate our ability to achieve results despite the macroeconomic environment that Joe referenced and that continues to be volatile,”​ Mongon said.

Looking ahead, he said J&J was advancing well on the carve-out of its newly named consumer health business Kenvue – set to be completed mid- to late-2023. The vision for the new business, he said, was to be modern and digital-first, associated with trust, care and science.

However, growth in 2023 would not be without its challenges, he said, with innovation set to prove key.

“We expect that the world will continue to be extremely volatile, with inflationary pressure, supply chain disruption, geopolitical environment, and continued impact from the COVID-19 pandemic in certain parts of the world. So, (…) with that in mind, we are certainly prepared to navigate this environment, thanks to the quality of our brands, [and] the strengthening of our execution capabilities around the world.”

Late last year, GlobalData analyst Alice Popple, said J&J was primed to become much more competition in personal care following the carve-out​ of its consumer health business, noting it would ensure a “more focused industry approach”.

Related news

Show more

Related products

show more

See our latest innovations in personal care

See our latest innovations in personal care

Content provided by Covation Bio™ PDO | 02-Apr-2024 | White Paper

At CovationBio PDO, we’re helping the world achieve its sustainability goals by enabling better performing, better-for-the planet products across a range...

Collagen Reimagined, Discover Biodesigned Type XXI

Collagen Reimagined, Discover Biodesigned Type XXI

Content provided by Geltor | 20-Mar-2024 | Product Brochure

Collagen is the body’s most abundant protein and a mainstream ingredient for beauty. Type XXI collagen transcends a common protein into a powerful bioactive

Empowering natural barrier function for future-proof skin

Empowering natural barrier function for future-proof skin

Content provided by Lucas Meyer Cosmetics | 14-Mar-2024 | White Paper

Corneopeptyl™ is a new patented peptide biomimetic to the LCE6A protein, obtained by green chemistry-based synthesis. By mimicking the LCE6A protein activity,...

Related suppliers

Follow us


View more


Beauty 4.0 Podcast